Today at 10:20 AM ET, Nadim Ahmed, President and CEO, and Jeff Jones, Chief Medical Officer, will participate in a fireside chat at the Cantor Fitzgerald Global Healthcare Conference in New York, NY.? ? A live webcast and recording will be available here:?https://bit.ly/4bD5WHU #CantorHCC
Cullinan Therapeutics
生物技术研究
Cambridge,Massachusetts 7,429 位关注者
Modality-Agnostic Targeted Therapeutics
关于我们
Cullinan Therapeutics is dedicated to creating new standards of care for patients. We have strategically built a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Our portfolio encompasses a wide range of modalities, each with the potential to be best and/or first in class. Anchored in a deep understanding of oncology, immunology, and translational medicine, we create differentiated ideas, identify the most appropriate targets, and select the optimal modality to develop transformative therapeutics across a wide variety of cancer and autoimmune indications. Notice to Job Seekers: Job applicants should be aware of job recruitment, interview and offer scams being perpetrated through the use of the internet and social media platforms. To learn more, visit our Careers page or read Cullinan’s Employment Recruitment Scams Notice here: https://cullinantherapeutics.com/docs/employment-recruitment-scams-notice.pdf
- 网站
-
https://www.cullinantherapeutics.com
Cullinan Therapeutics的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- Cambridge,Massachusetts
- 类型
- 上市公司
- 领域
- Oncology和Auto-Immune Diseases
地点
-
主要
1 Main St
US,Massachusetts,Cambridge,02142
Cullinan Therapeutics员工
动态
-
This #GynecologicCancerAwarenessMonth, we’re shedding a light on the need for more awareness and clinical research for cancers that affect the female reproductive system. ? ? With few treatment options currently available, our team is passionate about our research to pursue novel approaches to treating endometrial and cervical cancers. Learn more: https://bit.ly/3Xghixd
-
Today, we announced approval from the Human Research Ethics Committee in Australia to begin our global Phase 1 trial of CLN-978, a CD19xCD3 bispecific T cell engager, for the treatment of systemic lupus erythematosus (SLE).? ? SLE affects approximately 430,000 individuals globally. Currently available treatments do not routinely induce treatment-free remission, with most patients requiring lifelong immune suppression that treats symptoms without modifying the course of disease.? ? Today marks an important step in our efforts to bring a potential new treatment option to patients around the world living with SLE.? ? Learn more: https://bit.ly/4d8IL8c
-
Today, we announced the submission of an Investigational New Drug Application for CLN-978, a CD19xCD3 bispecific T cell engager, to treat systemic lupus erythematosus (SLE) to the U.S. FDA. ?? ? Currently available SLE treatments do not routinely induce treatment-free remission. Our goal is to bring a new therapeutic option to the 160,000+ patients impacted by SLE in the U.S.?? ? Learn more: https://bit.ly/3B97MTx
-
Today, we shared positive updated results from our pivotal Phase 2b REZILIENT1 trial in patients receiving zipalertinib after prior treatment with amivantamab at ESMO - European Society for Medical Oncology Congress. We also shared that enrollment of this trial has been completed ahead of schedule. Learn more: https://bit.ly/4e2yk7A ? #ESMO24?
-
While cytokines play a key role in immune system activation, clinical adoption of cytokine-based therapies for the treatment of cancer has been limited due to low response rates and severe toxicities. ? ? In a perspective piece in Frontiers in Oncology, our scientists discuss the potential of intratumoral delivery of cytokines optimized for tumor retention as a therapeutic solution that may address these limitations. ? ? We’re investigating the clinical potential of this approach with CLN-617, a collagen-binding fusion protein, that co-delivers IL-2 and IL-12 on a single molecule.? ? Read the full perspective: https://bit.ly/4716RjO?? ? #Immunotherapy #CancerResearch #FrontiersInOncology ?
-
Our team maintains an unrelenting focus to fulfill our purpose?of bringing new standards of care to patients by staying at the cutting edge of research. ? ? We look forward to seeing the latest emerging science in oncology at #ESMO24 and contributing to this important opportunity for scientific exchange.? ? On September 14 at 10:15 a.m. CEST, we will be sharing a mini oral presentation of updated findings for our lead investigational candidate in non-small cell lung cancer patients with insertions at exon 20. Learn more: https://bit.ly/4d1jtc9
-
Today at 4:05 PM ET, Nadim Ahmed, President and CEO, and Jeff Jones, Chief Medical Officer, will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference.?? ? A live webcast and recording will be available here: https://bit.ly/4bD5WHU ?
-
#BloodCancerAwarenessMonth is held every September to raise awareness of blood cancers, which affect the bone marrow, blood cells, lymph nodes, and other parts of the lymphatic system. Our team is advancing clinical research that may bring new standards of care to people living with relapsed and refractory #MultipleMyeloma and acute myeloid #leukemia (AML). https://bit.ly/3Xghixd
-
We’re pleased to welcome Sznol Mario, MD to our Scientific Advisory Board. Dr. Sznol has extensive experience in cancer immunotherapy and drug development in oncology. His background includes more than a decade in the Biologics Evaluation Section (BES), Investigational Drug Branch (IDB), Cancer Therapy Evaluation Program of the National Cancer Institute and 20 years as part of the medical oncology faculty at Yale. Dr. Sznol is currently a professor of internal medicine and co-leader of the Cancer Immunology Program at the Yale Comprehensive Cancer Center where he focuses on early drug development, immunotherapy, and treatments for advanced melanoma and kidney cancer. Dr. Sznol’s expertise will be invaluable as we continue to advance our diverse pipeline through clinical development. https://bit.ly/4amtj6W